Brief: Nexcella, An Immix Biopharma Subsidiary, Announces New Positive Nxc-201 Clinical Data Demonstrating 100% Complete Responses In Al Amyloidosis Patients + Additional Positive Multiple Myeloma Safety Data Demonstrating Nxc-201 Outpatient Car-T Treatment Potential
23/03/2023 13:13
March 23 (Reuters) - Immix Biopharma Inc IMMX.O :
* NEXCELLA, AN IMMIX BIOPHARMA SUBSIDIARY, ANNOUNCES NEW
POSITIVE
NXC-201 CLINICAL DATA DEMONSTRATING 100% COMPLETE RESPONSES IN
AL AMYLOIDOSIS PATIENTS + ADDITIONAL POSITIVE MULTIPLE MYELOMA
SAFETY DATA DEMONSTRATING NXC-201 OUTPATIENT CAR-T TREATMENT
POTENTIAL
Source text for Eikon: ID:nGNX8spxQF
Further company coverage: IMMX.O
((Reuters.Briefs@thomsonreuters.com;;))
Recent news on Immix Biopharma
See all newsBrief: Immix Biopharma Announces Closing Of $125 Million Underwritten Offering Of Common Stock
US RESEARCH ROUNDUP-Alnylam Pharmaceuticals, Carvana, MongoDB
Brief: Immix Biopharma Announces Pricing Of $125 Million Underwritten Offering Of Common Stock
Brief: Immix Biopharma Announces 89% Complete Response Rate At Interim Update Across All Nexicart-2 Patients, With Mrd-Negativity Indicating Potential To Reach Up To 98% Complete Response Rate
Immix Biopharma, Inc. reports results for the quarter ended June 30 - Earnings Summary